Evidence map›Paper›PMID 36422345›Full record

ArticleMicroorganisms2022

SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients.

Nayara Panizo, Estela Giménez, Eliseo Albert, Joao Zulaica, Alicia Rodríguez-Moreno, Luciana Rusu, Elena Giménez-Civera, Maria Jesús Puchades, Luis D'Marco, Lorena Gandía-Salmerón and 15 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Nayara PanizoNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Estela GiménezMicrobiology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, 46010 Valencia, Spain.
Eliseo AlbertMicrobiology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, 46010 Valencia, Spain.ORCID 0000-0002-5037-6095
Joao ZulaicaInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
Alicia Rodríguez-MorenoInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
Luciana RusuInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.ORCID 0000-0002-2481-4047
Elena Giménez-CiveraNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Maria Jesús PuchadesNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.ORCID 0000-0001-6927-071X
Luis D'MarcoUniversidad Cardenal Herrera-CEU Medicine Department, CEU Universities, 46115 Valencia, Spain.ORCID 0000-0003-0148-891X
Lorena Gandía-SalmerónNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Ignacio TorresMicrobiology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, 46010 Valencia, Spain.
Asunción SanchoNephrology Service, Transplant Unit, Hospital Universitario Dr. Peset, 46017 Valencia, Spain.
Eva GavelaNephrology Service, Transplant Unit, Hospital Universitario Dr. Peset, 46017 Valencia, Spain.
Miguel Gonzalez-RicoNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Marco MontomoliNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.ORCID 0000-0003-1412-6352
Carmen Maria Perez-BaylachB BraumAvitum Hemodialysis Centres Valnefron Valencia and Massamagrell, 46021 Valencia, Spain.
Begoña BonillaB BraumAvitum Hemodialysis Centres Valnefron Valencia and Massamagrell, 46021 Valencia, Spain.
Camila SolanoNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Mª Fernanda AlvaradoNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Isidro TorregrosaNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Boris Gonzales-CandiaNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
María Jesús AlcarazMicrobiology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, 46010 Valencia, Spain.
Ron GellerInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.ORCID 0000-0002-7612-4611
José Luis GórrizNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.ORCID 0000-0002-1134-9051
David NavarroNephrology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institutue, 46010 Valencia, Spain.
Hospital Clínico Universitario de Valencia · ESUniversitat de València · ESHospital Universitario Doctor Peset · ESUniversidad Cardenal Herrera CEU · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of a third vaccine dose (3D) of homologous mRNA vaccine on blood levels of SARS-CoV-2-receptor binding domain (RBD)-total antibodies was assessed in 40 hemodialysis patients (HD) and 21 kidney transplant recipients (KTR) at a median of 46 days after 3D. Anti-RBD antibodies were detected in 39/40 HD and 19/21 KTR. Overall, 3D boosted anti-RBD antibody levels (median: 58-fold increase). Neutralizing antibodies (NtAb) against the Wuhan-Hu-1, Delta, and Omicron variants were detected in 14, 13, and 11 out of 14 HD patients, and in 5, 5, and 4 out of 8 KTR patients, respectively. The median fold increase in NtAb titers in HD patients was 77, 28, and 5 and 56, 37, and 9 in KTR patients for each respective variant. SARS-CoV-2-S S-IFN-γ-producing CD8

Indexed as

hemodialysiskidney transplantationmRNA COVID-19 vaccineneutralizing antibodiesSARS-CoV-2-S antibodiesSARS-CoV-2-S T cells

Identifiers

PMID36422345
PMCPMC9694477
OpenAlexW4309607759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.